Skip to main content
. 2023 Sep 10;10(11):2155–2160. doi: 10.1002/acn3.51889

Figure 1.

Figure 1

Proposed treatment terms and definitions and potential paths for patient identification and treatment. DMT, disease‐modifying treatment; N, nusinersen; OA, onasemnogene abeparvovec; R, risdiplam; SMA, spinal muscular atrophy. SMN, survival motor neuron. aNusinersen/risdiplam discontinued, or no doses of nusinersen/risdiplam received after onasemnogene abeparvovec infusion.